GlassScriptPhysician profile
Kyle J Guidry
NPI 1619960812
$8,613.11
in general payments reported to CMS, 2019-2025
50 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $710 · 2021: $1,331 · 2022: $1,450 · 2023: $1,517 · 2024: $1,214 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,025.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,250.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $942.35 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $854.74 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $789.92 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Lilly USA, LLC | $691.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $494.74 | 2019-2025 | |
| Allergan, INC. | $337.35 | 2019-2020 | |
| Amgen INC. | $325.14 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $262.88 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.43 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Astellas Pharma US INC | $246.19 | 2019-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $217.99 | 2019-2024 | Livalo, Zoryve, Seglentis |
| Janssen Pharmaceuticals, INC | $157.20 | 2019-2022 | |
| Exact Sciences Corporation | $131.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.39 | 2019-2023 | Xifaxan, Trulance |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Guidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.